12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches

Table 1 (abstract P44). Long-term efficacy with 52-week open-label erenumab treatment after 12-week double-blind treatment in patients with chronic migraine

	Treatment failure subgroup			52-week OLE completers by last dose received
	Erenumab 70 mg/140 mgN=416			Erenumab 70 mgN=189^a		Erenumab 140 mgN=137^a
OLE visit weeks	Week 12n=395	Week 40n=300	Week 52n=261	Week 40n=166	Week 52n=150	Week 40n=124	Week 52n=109
Change from BL^b in MMD, mean (SE)	−6.84 (0.32)	−7.75 (0.38)	−8.58 (0.41)	−7.16 (0.48)	−7.86 (0.52)	−8.58 (0.62)	−9.66 (0.65)
Change from BL^b in MSMD, mean (SE)	−4.17 (0.26)	−4.78 (0.29)	−5.56 (0.34)	−4.75 (0.38)	−5.47 (0.43)	−4.93 (0.47)	−5.75 (0.54)
Percentage of patients with ≥50% response^c(95% CI)	40 (35, 44)	50 (44, 56)	55 (49, 61)	43 (36, 51)	49 (41, 57)	60 (51, 68)	63 (54, 72)

^aBased on the final dose of erenumab received. Patients in the erenumab 140 mg group received ≥3 months of erenumab 140 mg at Week 40 and ≥6 months of erenumab 140 mg at Week 52. ^bParent study baseline. ^c≥50% reduction in MMD from parent study baseline
BL, baseline; CI, confidence interval; MMD, monthly migraine days; MSMD, monthly acute migraine-specific medication treatment days; N, number of patients enrolled in the OLE and who failed ≥1 prophylactic treatment; n, number of patients with observed data at each time point; OLE, open-label extension; SE, standard error

ISSN: 1129-2377